my account log out | |
CTLA4[Biotinylated]:B7-2 Inhibitor Screening Assay Kit |
Create: 12/17/2018 |
Expired Date: | never |
Category: | Diagnostic equipment [Health&Medical&Pharmaceutical] |
Message: | B7-2 (CD86) signaling through CTLA4(CD152) has been shown to inhibit T cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host"s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer. https://www.creativebiomart.net/ctla4biotinylatedb7-2-inhibitor-screening-assay-kit-465598.htm |
City: | [US] |
Location: | |
Aug 25 2019 | Recombinant Human FGF2, None tagged | 400 | |
Aug 25 2019 | Recombinant Human PVRL2, None tagged | 411 | |
Aug 25 2019 | Recombinant Human PF4, None tagged | 419 | |
Aug 25 2019 | Recombinant Human CXADR, Fc-His tagged | 437 | |
Aug 25 2019 | Recombinant Mouse Cxadr, Fc-His tagged | 446 | |
Aug 25 2019 | Recombinant Human CX3CL1, His tagged | 439 | |
Aug 25 2019 | Recombinant Human CST5, His tagged | 398 | |
Aug 25 2019 | Recombinant Human CPE, Fc tagged | 407 | |
Aug 25 2019 | Recombinant Human Met, Fc-His tagged | 417 | |
Aug 25 2019 | Recombinant Human CEACAM1, His tagged | 413 |
Copyright © toextrade Inc. All rights reserved. Contact us |